Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Wall Street awaits Amgen weight-loss drug data expected to move shares https://t.co/xLpgAXdCzA https://t.co/yfkgYuv4kT
$AMGN (+0.1% pre) Wall Street awaits Amgen weight-loss drug data expected to move shares - Reuters https://t.co/dAGcnUPdsm
$AMGN - Wall Street awaits Amgen weight-loss drug data expected to move shares - https://t.co/iYimeJdoch
The recent volatility in key GLP-1 stocks has highlighted Wall Street's anxiety about the weight loss market. Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug, MariTide, is expected to provide insights into its efficacy compared to popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk. Wall Street is closely monitoring the data release, which is anticipated to significantly impact Amgen's stock performance. $AMGN shares are up 0.1% pre-market.